The Yōni.Fit device, constructed from 100% medical-grade silicone and manufactured entirely within the United States, is designed to be soft and flexible, facilitating comfortable self-insertion and removal. It is offered in six distinct sizes to accommodate variations in anatomy and is available either through healthcare provider prescription or directly online. This accessibility ensures broader reach and empowers women to manage their pelvic health proactively without the burden of invasive procedures or external devices.

Stress urinary incontinence—a condition characterized by involuntary urine leakage triggered by increased intra-abdominal pressure during activities such as physical exertion, coughing, or laughing—affects approximately two-thirds of women in the United States at some point in their lives. The impact on quality of life can be profound, influencing social engagement, psychological wellbeing, and even physical health. Prior to the Yōni.Fit, options for SUI were often limited to absorbent products that do not address the cause and can be inconvenient and uncomfortable. The Yōni.Fit’s FDA clearance in 2024 for up to 12 hours of continuous use marked a significant advancement in non-invasive SUI management.

The recent FDA labeling expansion of Yōni.Fit is a game-changer in the realm of menstrual hygiene, particularly for women who also experience stress urinary incontinence. The device now officially supports the safe collection of menstrual fluid and vaginal discharge alongside managing bladder leakage during menstruation. This innovation aligns with increasing user interest in menstrual cups, which are gaining popularity for their eco-friendly profile, reusability, and cost-effectiveness. Harvard Chan School of Public Health research indicates that around 20% of menstruating women in the U.S. currently use menstrual cups, especially those aged 18 to 35.

Clinical evidence supporting Yōni.Fit’s efficacy is robust, stemming from randomized, controlled, single-blind, multi-center trials involving women diagnosed with SUI. The device achieved over 96% reduction in clinically significant bladder leaks, underscoring its reliability and effectiveness as a pelvic health tool. Adverse effects reported were minor to moderate in severity, with no serious device-related complications, affirming Yōni.Fit’s safety profile for everyday use.

Clinicians specializing in urogynecology and reconstructive pelvic surgery endorse the device’s expanded utility. According to Dr. Karolynn Echols, a principal investigator in the clinical trials and Associate Professor at Thomas Jefferson University, Yōni.Fit offers patients a unique self-care option that extends beyond traditional incontinence products by integrating menstrual fluid management. Such dual functionality reduces reliance on disposable pads and tampons, which have detrimental environmental footprints.

Founder and CEO Allison L. Watkins emphasizes the longstanding demand from women for a versatile solution that addresses multiple leakages simultaneously. She highlights the device’s role in advancing environmental sustainability while maintaining clinical efficacy and user comfort. Watkins-Conti’s innovation underlines a trend toward patient-centered design in medical devices that deeply understand users’ lived experiences.

Given the device’s prescription status and inclusion in Health Savings Account (HSA) eligibility, Yōni.Fit may be covered under select insurance plans, improving affordability. Healthcare providers can easily integrate the device into their practice through specialized stocking options provided by Watkins-Conti, which supports a smooth prescribing and supply chain experience.

The company’s strategic vision extends well beyond the Yōni.Fit, aiming to build a comprehensive pipeline of pelvic health innovations backed by a strong intellectual property portfolio. With multiple U.S. and international patents, Watkins-Conti is securing its position at the forefront of women’s healthcare technologies, focused on delivering clinical solutions that are both accessible and effective.

In conclusion, the expanded FDA clearance of Yōni.Fit as both an SUI treatment and a menstrual fluid collector marks a significant milestone in female pelvic health innovation. This development not only enhances the quality of life for millions of women but also contributes to environmental sustainability and women’s autonomy over their bodies. Offerings such as Yōni.Fit represent the next generation of pelvic health solutions, blending clinical sophistication with practical usability in everyday life.

Subject of Research: Women’s pelvic health devices, stress urinary incontinence, menstrual fluid management
Article Title: Watkins-Conti’s Yōni.Fit: Revolutionizing Pelvic Health with Dual-Use Vaginal Insert
News Publication Date: April 23, 2026
Web References:

• https://yonifit.com/
• https://hsph.harvard.edu/research/apple-womens-health-study/study-updates/menstrual-hygiene-products-pads-and-tampons-are-the-go-to-choice/#:~:text=This%20was%20a%20%E2%80%9Cchoose%20all%20that%20apply%E2%80%9D%20question%3B%20therefore,reported%20by%20other%20age%20groups.
• https://journals.lww.com/fpmrs/Abstract/2022/04000/Updated_Prevalence_of_Urinary_Incontinence_in.1.aspx
• https://journals.lww.com/fpmrs/fulltext/9900/a_randomized_controlled_trial_of_a_novel_device.383.aspx
  Image Credits: Watkins-Conti Products, Inc.
  Keywords: stress urinary incontinence, pelvic health, menstrual fluid management, vaginal insert, Yōni.Fit, FDA clearance, women’s health innovation, urogynecology, medical-grade silicone, menstrual cup alternative

The clinical trial titled “A Randomized Controlled Trial of a Novel Device for Stress Incontinence” has been published in the reputable journal Urogynecology, the official publication of the American Urogynecologic Society. This multidisciplinary journal focuses on the prevention, diagnosis, and treatment of female pelvic floor disorders, making it an ideal platform for disseminating results related to innovations in women’s pelvic health care. The study delivers rigorous evidence in support of Yōni.Fit®, reinforcing its potential as a leading front-line solution for SUI management.

Conducted at prominent medical institutions including Stanford, NYU Langone, and Jefferson Health, the randomized, controlled, single-blind, multi-center trial enrolled women over the age of 18 living with stress urinary incontinence. The methodology ensured robust data collection and analysis, with outcomes focusing on reductions in urine leakage. Specifically, the study measured 12-hour pad weights over a seven-day period to quantify leakage accurately. Participants using Yōni.Fit® demonstrated statistically significant improvements compared to those using control devices, underscoring the bladder support’s superior efficacy in managing symptoms discreetly and effectively.

One of the most compelling aspects of Yōni.Fit® is its design and material composition. Manufactured entirely in the United States from 100% medical-grade silicone, the device is soft, flexible, and self-administered. This allows women to insert and remove the support on their own, offering autonomy and convenience. Importantly, the insert can be used during targeted activities known to exacerbate SUI symptoms or for up to 12 hours for sustained control. The device’s ergonomic design is the result of extensive research and development, including patient feedback and clinical validation, positioning it as a pioneering product in the market of pelvic floor health devices.

Healthcare professionals specializing in women’s health have already endorsed Yōni.Fit®. Dr. Darren Walter Goff, an experienced OB-GYN, highlights the device’s value for postpartum patients, many of whom develop stress incontinence but may not be ready or willing to pursue surgical interventions. The ability to prescribe Yōni.Fit® following a single office or telehealth visit means that relief can be initiated promptly, reducing the burden of prolonged discomfort and improving patient outcomes. This represents a significant shift toward minimally invasive, patient-centric management of SUI.

Dr. Karolynn T. Echols, an authoritative figure in Female Pelvic Medicine and Reconstructive Surgery at Thomas Jefferson University and a lead investigator in the clinical study, emphasized the clinical advantages. According to Dr. Echols, Yōni.Fit® not only demonstrated meaningful reductions in urinary leakage but also did so safely, with no serious adverse events reported. Mild to moderate adverse effects were documented among some participants but were not directly associated with device use, reinforcing Yōni.Fit®’s strong safety profile and tolerability.

From a manufacturing and distribution standpoint, Watkins-Conti has positioned Yōni.Fit® to achieve wide accessibility. National distribution partnerships facilitate the availability of self-sizing kits, enabling women nationwide to select the appropriate device size from the comfort of their homes. These logistical strategies remove typical barriers related to pelvic health device fitting and access, such as multiple clinical visits or specialized in-person fittings, which historically limited uptake and adherence.

Moreover, the Very Important Provider (VIP) Kit concept is transforming clinical practice integration. Designed to streamline incorporation into primary care, OB-GYN, urology, and urogynecology settings, the VIP kit provides healthcare providers with education, patient materials, and the necessary tools to prescribe Yōni.Fit® effectively. This strategy supports the growing shift toward integrating preventive and conservative management of pelvic floor disorders within routine clinical care pathways.

Yōni.Fit® is also financially accessible. It is covered by most leading commercial and government insurance plans and is eligible for purchase via Health Savings Accounts (HSA). Customers can obtain the device through in-person consultations or telehealth prescriptions, and fulfillment is managed by Edgepark, a well-established healthcare supply distributor and Cardinal Health business unit. This payer coverage and streamlined purchase process enhances affordability and convenience, ensuring that cost or logistical constraints do not impede access.

Stress urinary incontinence represents a significant healthcare challenge affecting millions of women yet remains underdiagnosed and undertreated due to stigma, lack of awareness, and limited non-surgical options. Devices like Yōni.Fit® mark a pivotal advancement, providing a scientifically substantiated, user-centered solution that empowers women to regain control over their bodies without invasive treatments. The published clinical data corroborating its efficacy and safety provide an evidence-based foundation for broader clinical acceptance.

Watkins-Conti, under the leadership of founder and CEO Allison L. Watkins, continues to innovate within women’s pelvic health. Holding a broad portfolio of utility and design patents, the company exemplifies the fusion of patient-driven design and advanced biomedical technology. By focusing on non-surgical, patient-friendly management tools, Watkins-Conti envisions a future where pelvic health concerns are addressed proactively, reducing morbidity and enhancing the everyday lives of women globally.

In conclusion, the peer-reviewed validation of Yōni.Fit®’s clinical benefits heralds a significant milestone. This novel device redefines the standard of care for managing stress urinary incontinence by combining technical innovation, user-centric design, and clinical robustness. As the medical community increasingly acknowledges the impact of pelvic floor disorders, solutions like Yōni.Fit® will likely become foundational components of comprehensive women’s health strategies in the years ahead.

Subject of Research: People

Article Title: A Randomized Controlled Trial of a Novel Device for Stress Incontinence

News Publication Date: May 13, 2025

Web References:

• Clinical trial publication: https://journals.lww.com/fpmrs/fulltext/9900/a_randomized_controlled_trial_of_a_novel_device.383.aspx
• Product information: https://yonifit.com/
• FDA 510(k) clearance (implied in text)

References:

• Watkins-Conti Products, Inc. press release and clinical trial data
• Urogynecology Journal, 28-Apr-2025, DOI: 10.1097/SPV.0000000000001676

Image Credits: Watkins-Conti Products, Inc.

Keywords: Gynecology, Clinical Studies, Urology, Obstetrics, Family Medicine